Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

MCRB Seres Therapeutics, Inc.
$1.41 0.71% +0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy MCRB stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Seres Therapeutics, Inc. (MCRB)

Loading

Key Stats

Market cap. 14.4M
Enterprise value 32.5M
Trailing PE 11.71875
Forward PE -0.71979433
PEG Ratio -0.097085994525547
Enterprise to EBITDA -0.514
Enterprise to revenue 15.302
Price to book MRQ 0.6588235
Price to sales TTM 6.7167263

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 2.1M
EBITDA -63311000
Diluted EPS TTM -5.01
Total Cash (MRQ) 17.5M
Current ratio (MRQ) 1.648
Operating Cash Flow (TTM) -63941000

MCRB trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent MCRB News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.